ArticlePsychopharmacology2026
Adolescent anodal tDCS ameliorates behavioral deficits and microglial abnormalities in a maternal immune activation mouse model of schizophrenia.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranscranial direct current stimulation (tDCS) shows promise as a treatment for schizophrenia, but its mechanisms, particularly during critical developmental windows and its impact on neuroimmune cells such as microglia, remain poorly understood.
objectiveWe investigated whether adolescent anodal tDCS could ameliorate behavioral deficits in a maternal immune activation (MIA) mouse model of schizophrenia by rectifying microglial abnormalities.
methodsC57BL/6 offspring from Poly I:C- or saline-injected dams received frontal anodal tDCS or sham stimulation during adolescence. Behavioral tests for spontaneous locomotor activity, anxiety, cognition and sensorimotor gating were conducted. Microglial cell count, morphology, and phagocytic activity were assessed in the medial prefrontal cortex (mPFC) and hippocampus via immunofluorescence. Serum cytokines were measured by ELISA, and transcriptomic profiling of brain tissue was performed via RNA-seq.
resultsMIA offspring exhibited cognitive deficit, accompanied by microglial abnormalities in the mPFC and hippocampus. While adolescent anodal tDCS normalized these phenotypes in MIA mice, it conversely induced cognitive deficits and reduced hippocampal microglial complexity in control mice. Strikingly, tDCS bidirectionally regulated microglial phagocytosis, enhancing it in MIA mice while suppressing it in control mice. RNA-seq of the mPFC revealed that tDCS modulated genes related to neuronal activation (e.g., Fos, JunB) and neural repair (e.g., Sparc), enriching pathways like MAPK signaling and neurotransmitter transport, whereas no significant alterations were observed in the hippocampal transcriptome. Moreover, tDCS elicited a peripheral pro-inflammatory state, elevating serum IL-6 and TNF-α.
conclusionOur findings demonstrated that adolescent anodal tDCS reversed schizophrenia-relevant deficits by promoting microglial normalization in a state- and region-dependent manner, highlighting its potential as an early intervention during critical neurodevelopment.
Indexed as
Identifiers
41896350What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.